2nd Quarter - Report
HOSPIRA, INC. for HOSPIRA INC
Firm
Client
Income
—
Expenses
$240,000
Expense method
A: Lobbying Disclosure Act definitions
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Implementation of the Biologics Price Competition and Innovation Act (BPCIA) relating to biosimilar naming. Issues relating to opiate overdosing. Issues related to drug approvals at the FDA including biosimilars.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JULIANA REED | — |
| WENDY SUSSMAN | — |
Pharmacy PHA
Issues relating to drug shortages, patent use codes and drug labeling (RIN:0910-AG94: FDA Proposed Rule on Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products).
| Lobbyist | Covered position, as disclosed |
|---|---|
| JULIANA REED | — |
| WENDY SUSSMAN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.